TY - JOUR
T1 - A CRISPR-guided mutagenic DNA polymerase strategy for the detection of antibiotic-resistant mutations in M. tuberculosis
AU - Feng, Siyuan
AU - Liang, Lujie
AU - Shen, Cong
AU - Lin, Daixi
AU - Li, Jiachen
AU - Lyu, Lingxuan
AU - Liang, Wanfei
AU - Zhong, Lan lan
AU - Cook, Gregory M.
AU - Doi, Yohei
AU - Chen, Cha
AU - Tian, Guo bao
N1 - Funding Information:
This work was supported by the National Natural Science Foundation of China (grant numbers 82061128001 , 81830103 to G.-B.T., grant number 82002173 to S.F.), Guangdong Natural Science Foundation (grant number 2017A030306012 to G.-B.T.), National Key Research and Development Program (grant number 2017ZX10302301 to G.-B T.), Project of High-level Health Teams of Zhuhai in 2018 (The Innovation Team for Antimicrobial Resistance and Clinical Infection to G.-B.T.), and the Project 111 (grant number B12003 to G.-B.T.).
Publisher Copyright:
© 2022 The Authors
PY - 2022/9/13
Y1 - 2022/9/13
N2 - A sharp increase in multidrug-resistant tuberculosis (MDR-TB) threatens human health. Spontaneous mutation in essential gene confers an ability of Mycobacterium tuberculosis resistance to anti-TB drugs. However, conventional laboratory strategies for identification and prediction of the mutations in this slowly growing species remain challenging. Here, by combining XCas9 nickase and the error-prone DNA polymerase A from M. tuberculosis, we constructed a CRISPR-guided DNA polymerase system, CAMPER, for effective site-directed mutagenesis of drug-target genes in mycobacteria. CAMPER was able to generate mutagenesis of all nucleotides at user-defined loci, and its bidirectional mutagenesis at nick sites allowed editing windows with lengths up to 80 nucleotides. Mutagenesis of drug-targeted genes in Mycobacterium smegmatis and M. tuberculosis with this system significantly increased the fraction of the antibiotic-resistant bacterial population to a level approximately 60- to 120-fold higher than that in unedited cells. Moreover, this strategy could facilitate the discovery of the mutation conferring antibiotic resistance and enable a rapid verification of the growth phenotype-mutation genotype association. Our data demonstrate that CAMPER facilitates targeted mutagenesis of genomic loci and thus may be useful for broad functions such as resistance prediction and development of novel TB therapies.
AB - A sharp increase in multidrug-resistant tuberculosis (MDR-TB) threatens human health. Spontaneous mutation in essential gene confers an ability of Mycobacterium tuberculosis resistance to anti-TB drugs. However, conventional laboratory strategies for identification and prediction of the mutations in this slowly growing species remain challenging. Here, by combining XCas9 nickase and the error-prone DNA polymerase A from M. tuberculosis, we constructed a CRISPR-guided DNA polymerase system, CAMPER, for effective site-directed mutagenesis of drug-target genes in mycobacteria. CAMPER was able to generate mutagenesis of all nucleotides at user-defined loci, and its bidirectional mutagenesis at nick sites allowed editing windows with lengths up to 80 nucleotides. Mutagenesis of drug-targeted genes in Mycobacterium smegmatis and M. tuberculosis with this system significantly increased the fraction of the antibiotic-resistant bacterial population to a level approximately 60- to 120-fold higher than that in unedited cells. Moreover, this strategy could facilitate the discovery of the mutation conferring antibiotic resistance and enable a rapid verification of the growth phenotype-mutation genotype association. Our data demonstrate that CAMPER facilitates targeted mutagenesis of genomic loci and thus may be useful for broad functions such as resistance prediction and development of novel TB therapies.
UR - http://www.scopus.com/inward/record.url?scp=85135709387&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135709387&partnerID=8YFLogxK
U2 - 10.1016/j.omtn.2022.07.004
DO - 10.1016/j.omtn.2022.07.004
M3 - Article
AN - SCOPUS:85135709387
VL - 29
SP - 354
EP - 367
JO - Molecular Therapy - Nucleic Acids
JF - Molecular Therapy - Nucleic Acids
SN - 2162-2531
ER -